The Department of Veterans Affairs intends to award a sole-source contract to Cepheid for the provision of molecular platform reagents specifically for the Orlando Healthcare System. This procurement is being conducted under the authority of 41 USC 3304(a)(1) and FAR 6.302-1, highlighting the specialized nature of the reagents required for in-vitro diagnostics. The selected vendor will be responsible for supplying essential diagnostic substances, which play a critical role in patient care and treatment decisions. Interested vendors who believe they can meet the requirements must submit a complete technical package to Contract Specialist Benjamin Amato by January 30, 2024, at 1:00 PM Eastern Standard Time, with no compensation provided for submitted information.